DXSP DXS International Plc

 
TIDMDXSP 
 
 
   DXS INTERNATIONAL PLC 
 
   (AQSE: DXSP) 
 
   Update on Hypertension Pilot Programme 
 
   DXS International plc ("DXS", the "Company"), the digital clinical 
decision support Company, is pleased to update shareholders on its 
ExpertCare hypertension solution pilot programme. 
 
   Managing patients on medication for hypertension is complex, exacerbated 
by the fact that more than 60% of hypertensives have one or more 
comorbidity such as Diabetes, Atrial Fibrillation, or COPD. While UK 
guidelines on how to treat this exist, getting the medicines combination 
and dosages correct for all hypertensive patients is extremely difficult 
for busy clinicians. 
 
   DXS has invested five years and over GBP1.5 million creating ExpertCare 
which is able to analyse and interpret a patient's electronic record and 
instantly present prescribing recommendations. There are currently 12 
pilots live at various stages, with a total of 30 pilots planned, each 
with a minimum of at least 30 patients in each pilot. Initial results 
from four completed pilots in GP practices are encouraging: 
 
 
   -- Patient non-compliance with prescribed treatment was reduced from 41% to 
      21%; 
 
   -- Prescribing regimen particularly in patients with comorbidities improved 
      in 15% of cases; 
 
   -- The system is seen as intuitive and easy to use; 
 
   -- Where the system recommended changes to clinician decisions, these were 
      on closer inspection fully accepted by the relevant clinicians as correct 
      and indeed needing change; and 
 
   -- GPs using the ExpertCare system considered that it could empower nurses 
      and pharmacists to conduct the majority of hypertension consultations 
      with minimal GP input. 
 
 
   The benefit to GP practices is estimated to be a potential saving of 330 
GP hours for a 9,000-patient practice, easing the pressure on 
hard-pressed GPs and worth GBP25,000 p.a. per practice based on the 
pilot group. Extrapolated across the UK, this equates to GBP187 million 
p.a. or the equivalent of 2,000 full time GPs. 
 
   The UK has 10 million diagnosed hypertensive patients and it is clear 
that effectively controlling blood pressure reduces heart attacks, 
strokes, and kidney disease. Public Health England estimates that 
through optimal anti-hypertensive treatment, 9,000 heart attacks and 
14,000 strokes could be prevented over 3 years. This equates to a saving 
of GBP272 million for the NHS. 
 
   Additional pilots are still in progress and DXS is working closely with 
NHS stakeholders to complete a global best of breed hypertension 
solution that will deliver significant Return on Investment to 
healthcare providers, help plug the GP shortage gap and improve patient 
outcomes by increasing compliance and averting unnecessary 
complications. 
 
   Spurred on by the positive UK results, we have also started planning for 
pilots in carefully selected markets outside the UK. Early research and 
demonstrations to potential users are encouraging as the same 
hypertension problems remain, and potential returns are higher. 
 
   David Immelman, Chief Executive of DXS said: "We are extremely excited 
and encouraged by these early results and, as the situation begins to 
normalise in the UK, we anticipate being able to expand marketing of the 
ExpertCare solution throughout the UK and internationally. We were 
delighted to gain CE accreditation for this product and await GPITF 
(NHS) accreditation which has been somewhat delayed by COVID. In the 
meantime, we are continuing our pilot programme, adding positive 
enhancements and optimising this solution." 
 
   The Directors of DXS International plc accept responsibility for this 
announcement. 
 
   Contacts: 
 
 
 
 
David Immelman (Chief Executive)               01252 719800 
 DXS International plc                david@dxs-systems.com 
https://www.dxs-systems.co.uk 
 
 
 
 
 
 
Corporate Advisor 
City & Merchant 
 David Papworth     020 7101 7676 
 
 
 
 
 
 
Corporate Broker 
Hybridan LLP 
 Claire Louise Noyce   020 3764 2341 
 
 
   Notes to Editors 
 
   About DXS: 
 
   DXS International presents up to date treatment guidelines and 
recommendations, from Clinical Commissioning Groups and other trusted 
NHS sources, to doctors, nurses and pharmacists in their workflow and 
during the patient consultation. This effective clinical decision 
support ultimately translates to improved healthcare outcomes delivered 
more cost effectively and which should significantly contribute towards 
the NHS achieving its projected efficiency savings. 
 
 
 
 

(END) Dow Jones Newswires

February 04, 2021 02:00 ET (07:00 GMT)

DXS (AQSE:DXSP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

DXS (AQSE:DXSP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024